Loading...
XSTO
MAGNA
Market cap1mUSD
Jul 08, Last price  
0.43SEK
Name

Aegirbio AB

Chart & Performance

D1W1MN
P/E
—
P/S
167.72
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
503.67%
Revenues
92k
-94.61%
013,282,0001,706,00092,000
Net income
-60m
L-83.55%
-10,347,000-92,329,000-362,830,000-59,696,000
CFO
-42m
L-14.40%
-7,405,000-109,371,000-48,997,000-41,939,000

Profile

AegirBio AB (publ), a diagnostic company, develops and commercializes tests to follow the dosage of biological drugs. The company focuses on therapeutic drug monitoring of biologic therapies in the multiple sclerosis, cancer, and autoimmune diseases. It offers moNATor, a first dose-monitoring laboratory test to test multiple sclerosis for healthcare professionals and patients; and Viraspec, a COVID-19 saliva test kit. The company was incorporated in 2019 and is based in Lund, Sweden.
URL
https://aegirbio.com/
IPO date
Jun 26, 2020
Employees
15
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑12
Income
Revenues
92
-94.61%
1,706
-87.16%
Cost of revenue
60,608
93,186
Unusual Expense (Income)
NOPBT
(60,516)
(91,480)
NOPBT Margin
Operating Taxes
(1,493)
(1,483)
Tax Rate
NOPAT
(59,023)
(89,997)
Net income
(59,696)
-83.55%
(362,830)
292.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,356
40,391
BB yield
Debt
Debt current
639
6,728
Long-term debt
32,761
2,320
Deferred revenue
Other long-term liabilities
8,132
4,118
Net debt
20,974
(5,540)
Cash flow
Cash from operating activities
(41,939)
(48,997)
CAPEX
(93)
(65)
Cash from investing activities
(5,538)
(65)
Cash from financing activities
45,046
29,261
FCF
(57,489)
(82,736)
Balance
Cash
12,142
14,588
Long term investments
284
Excess cash
12,421
14,503
Stockholders' equity
(530,149)
(472,899)
Invested Capital
569,786
523,997
ROIC
ROCE
EV
Common stock shares outstanding
29,089
21,881
Price
Market cap
EV
EBITDA
(60,516)
(79,165)
EV/EBITDA
Interest
10,001
218
Interest/NOPBT